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The current standard of care for metastatic urothelial carcinoma is cisplatin-based
chemotherapy but treatment is generally not curative. Mechanisms of resistance to conven-
tional cytotoxic regimens include tumor cell drug efflux pumps, intracellular anti-oxidants,
and enhanced anti-apoptotic signaling. Blockade of signaling pathways with small molecule
tyrosine kinase inhibitors has produced dramatic responses in subsets of other cancers.
Multiple potential signaling pathway targets are altered in Urothelial carcinoma (UC). Block-
ade of the PI3K/Akt/mTOR pathway may prove efficacious because 21% have activating
PI3K mutations and another 30% have PTEN inactivation (which leads to activation of this
pathway). The fibroblast growth factor receptor 3 protein may be overactive in 50–60%
and agents which block this pathway are under development. Blockade of multiple other
pathways including HER2 and aurora kinase also have potential efficacy. Anti-angiogenic
and immunotherapy strategies are also under development in UC and are discussed in this
review. Novel therapeutic approaches are needed in UC. We review the various strategies
under investigation and discuss how best to evaluate and optimize their efficacy.
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INTRODUCTION
Urothelial carcinoma (UC) affects an estimated 76,000 people in
the USA each year and causes 16,000 deaths (Siegel et al., 2012).
The majority of cases are localized to the urinary tract but 25%
present with or develop locally advanced or metastatic disease
which is generally incurable (Bellmunt and Petrylak, 2012). The
current standard of care for metastatic disease is combination
chemotherapy with cisplatin and gemcitabine. This regimen was
found to be equally effective but less toxic than the quadruplet
methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) regimen
which had been the previous standard (von der Maase et al., 2000).
Cisplatin/gemcitabine had a response rate of 49%, median pro-
gression free survival of 8 months, overall survival of 14 months,
and 13% of patients survived ≥5 years. The median duration of
response was 10 months but a minority of patients did achieve a
durable complete remission (von der Maase et al., 2005).
MECHANISMS OF RESISTANCE TO CISPLATIN
CHEMOTHERAPY
Cisplatin is the cornerstone of chemotherapy for metastatic UC.
It acts by binding to purine DNA bases, forming inter- and intra-
strand crosslinks, causing DNA damage, and thus activating the
apoptotic pathway leading to cell death (Drayton and Catto, 2012).
Multiple mechanisms of UC resistance to cisplatin have been iden-
tified and can be broadly classified into tumor cell drug efflux
pumps, intracellular anti-oxidants, DNA repair pathway modula-
tion, and enhanced anti-apoptotic signaling (Drayton and Catto,
2012).
The main mechanism of cisplatin efflux from the cell is by the
ATP7A and ATP7B proteins (Komatsu et al., 2000; Samimi et al.,
2004). Increased expression of these proteins is associated with
cisplatin resistance in some tumor types including ovarian can-
cer (Samimi et al., 2004). However, in UC it appears that increased
cisplatin efflux is not a major mechanism of resistance and accord-
ingly a recent study in UC cell lines showed no correlation between
levels of intracellular cisplatin and sensitivity to the drug (Yu and
Wang, 2012).
Intracellular binding and sequestration of cisplatin by thiol
proteins like metallothioneins and glutathione can also neu-
tralize its activity (Drayton and Catto, 2012). Increased expres-
sion of both metallothioneins and glutathione has been cor-
related with UC resistance to cisplatin in cell line studies
(Siegsmund et al., 1999; Byun et al., 2005). At a clinical level,
absence of UC metallothionein expression by immunohisto-
chemistry and low levels of glutathione as measured by liquid
chromatography are correlated with response to neoadjuvant
cisplatin-based chemotherapy (Bahnson et al., 1994; Yang et al.,
1997).
ERCC1 is a protein involved in repairing DNA which is dam-
aged by cisplatin. Increased expression in cancer cells is corre-
lated with shorter survival after treatment with cisplatin-based
chemotherapy (Bellmunt et al., 2007). Defects in the ability of
cancer cells to recognize DNA damage and undergo apoptosis also
play a role in cisplatin resistance. Bcl-2 is an anti-apoptotic protein
which is upregulated in UC and in cell line studies knock-down
of Bcl-2 expression rendered previously resistant cells sensitive to
cisplatin (Hong et al., 2002). p53 is the most commonly mutated
gene in human cancers and cell line studies have found that these
mutations may increase cisplatin resistance in UC (Drayton and
Catto, 2012). However, attempts to use this finding for treatment
stratification in the clinic have so far proved fruitless (Stadler et al.,
2011).
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Mechanisms of UC resistance to gemcitabine have been less
well studied but putative factors include upregulation of heme-
oxygenase 1 and the anti-apoptotic protein clusterin (Mura-
maki et al., 2009; Miyake et al., 2010). Gemcitabine resistance
has been more extensively investigated in other cancers and
researchers have found resistance associated with upregulation of
heat shock protein 27 (further discussed below) and multidrug
membrane transport proteins (ABCG2 and ABCA9) in pancre-
atic cancer and upregulation of bcl-2 in breast and gastric cancer
(Kuramitsu et al., 2012; Van den Broeck et al., 2012; Wong et al.,
2012).
EFFORTS TO IMPROVE THE EFFICACY OF CYTOTOXIC
CHEMOTHERAPY
In an effort to improve outcomes with cisplatin/gemcitabine a
phase 3 trial assessed the addition of paclitaxel to this regimen
(Bellmunt et al., 2012). While response rate was improved from
44 to 56% with the addition of paclitaxel, there was no signif-
icant improvement in overall survival. An analysis of patients
in this trial with tumors of bladder origin (rather than upper
tract UC) did reveal a statistically significant survival improve-
ment although this was a post hoc subset analysis (Bellmunt et al.,
2012).
Another strategy to improve outcomes with conventional
chemotherapy is dose intensification using growth factor sup-
port. Human cancer cells grow by Gompertzian kinetics whereby
growth rates decrease with increasing tumor size (Norton, 1988).
Dose-dense scheduling is designed to capitalize on this phe-
nomenon by delivering successive cycles of chemotherapy at
shorter intervals when the residual tumor burden is smaller,
faster growing, and hence more chemosensitive (Morris et al.,
2010). It also allows higher cumulative doses of chemother-
apy to be administered in a given time-frame. The approach
has been successful in the adjuvant treatment of breast can-
cer, although did not improve outcomes in diffuse large B cell
lymphoma (Citron et al., 2003; Cunningham et al., 2011). In
metastatic UC, a phase 3 clinical trial evaluated classic MVAC
given every 28 days against a dose-dense MVAC regimen admin-
istered every 14 days with granulocyte colony stimulating factor
support. There was no significant median overall survival bene-
fit with the dose-dense approach in this study. However response
rates were improved and a larger number of patients did appear
to gain long term disease remission [5 year progression free sur-
vival (16.5 vs. 8%) and overall survival (22 vs. 14%) favoring
intensified chemotherapy; Sternberg et al., 2006]. Dose intensi-
fied gemcitabine/cisplatin appears to be a promising alternative
with a lower toxicity profile based on preliminary reports of an
aborted phase III trial (Bamias et al., 2012). This regimen is
being further tested in the neoadjuvant setting (NCT01589094
and NCT01611662).
Heat shock proteins are a class of proteins which are upreg-
ulated during cellular stress. Among their numerous functions
include acting as “molecular chaperones” to stabilize signaling
molecules which may include oncogenic proteins (Richardson
et al., 2011). In UC,HSP 70-2 is over-expressed and knock-down of
its expression in xenograft studies suppressed tumor growth (Garg
et al., 2010). Recent mouse model work has shown the potential
of a HSP 90 inhibitor to overcome cisplatin resistance (Tatokoro
et al., 2012). HSP 27 is also implicated in UC chemoresistance and
an anti-sense oligonucleotide targeting its expression is currently
under active investigation in a randomized phase 2 trial combin-
ing it with chemotherapy (NCT01454089; Kamada et al., 2007;
Hadaschik et al., 2008).
Another route to improving the effectiveness of cytotoxic
chemotherapy in UC is to prospectively identify those patients
most likely to respond. This would maximize the benefits from
chemotherapy and spare many patients unnecessary toxicity. To
this end, identification and validation of potential predictive
tumor biomarkers such as ERCC1, Ribonucleotide reductase sub-
unit M1 (RRM1), BRCA1, and miR-34a is warranted (Chang
et al., 2012). In addition, germline polymorphisms may pro-
vide information about the likelihood of response to a given
treatment. In UC, Gallagher et al. (2011a) identified four single
nucleotide polymorphisms (SNPs) which predicted a likelihood
of response to chemotherapy varying from 19 to 84%. A com-
posite germline and somatic genetic signature could prove to be
more predictive than either one alone (Bambury and Gallagher,
2012).
NOVEL APPROACHES TO THE TREATMENT OF METASTATIC
UROTHELIAL CANCER MAY OVERCOME THERAPEUTIC
RESISTANCE
SIGNALING PATHWAY BLOCKADE
Of the thousands of genetic alterations in a given cancer cell there
are likely to be only a few “driver” mutations which have a signifi-
cant pro-neoplastic effect (Torti et al., 2012). The growth and sur-
vival of some cancers is dependent on the continued over-activity
of certain signaling pathways due to these driver mutations, which
is known as “oncogene addiction” (Weinstein, 2002). Small mol-
ecule tyrosine kinase inhibitors (TKIs) block signaling through
the relevant pathway and induce cell-cycle arrest, differentiation,
or apoptosis (Torti and Trusolino, 2011). Clinical examples of the
implementation of this principle for patient benefit include using
imatinib to block bcr-abl signaling in chronic myeloid leukemia
and vemurafenib to block mutated BRAF signaling in melanoma
(O’Brien et al., 2003; Chapman et al., 2011). While the clinical
benefit of targeting oncogenic activating mutations has not been
proven in UC, there are multiple potential molecular targets with
tantalizing hints of efficacy beginning to appear (Figure 1; Iyer
et al., 2012).
The PI3K/Akt/mTOR pathway is one potential therapeutic
target. Approximately 21% of muscle invasive UC have activat-
ing PI3K mutations, while another 30% demonstrate evidence
of PTEN inactivation (Ching and Hansel, 2010; Kompier et al.,
2010). In addition, 16% of patients have inactivating mutations in
TSC1, an inhibitor of mTOR activation. Indeed, a recently pub-
lished report in Science describes a durable complete response to
everolimus in a patient with chemotherapy refractory metasta-
tic UC in which an inactivating mutation in the TSC1 gene was
identified. In that study, four of five patients with TSC1 muta-
tion experienced objective tumor shrinkage, compared with one
of nine patients without TSC1 mutation. These findings raise the
possibility that mTOR inhibition may be an effective therapeu-
tic strategy for the subset of metastatic UC patients with genetic
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FIGURE 1 | Major oncogenic signaling pathway alterations in
urothelial carcinoma. Each potential target is identified with the
proportion of muscle invasive UC known to have oncogenic alterations in
the signaling molecule. Superscript denotes reference article. 1Lae et al.,
2010; 2Tomlinson et al., 2007a; 3Kompier et al., 2010; 4Ching and Hansel,
2010; 5Boulalas et al., 2009
activation of the PI3K/Akt/mTOR pathway. However, in unse-
lected patients, everolimus showed disappointing results, with a
5% response rate (Seront et al., 2012). Retrospective analysis of
this trial revealed that presence of PI3K mutations did not neces-
sarily correlate with response, highlighting the fact that therapeutic
manipulation of molecular pathways may be more complex than
simply targeting tumors with evidence of mutational pathway acti-
vation (Seront et al., 2012). In another study enrolling patients of
all tumor types in early phase clinical trials of regimens including
PI3K/AKT/mTOR inhibitors, the authors found a 17% response
rate in patients with known PI3K pathway alteration (as evidenced
by PIK3CA mutations, PTEN aberrations, or both) compared with
6% in those without (Janku, 2012). Furthermore, the presence of
a synchronous activating k-ras mutation decreased likelihood of
response to 4% and treatment with monotherapy had an inferior
response rate (2.5%) compared with treatment using dual pathway
blockade (23%). Future trials enriching for potential responders
by accruing patients based on mutational profiles may improve
the therapeutic index.
The ERBB2 gene encoding the HER2 protein is amplified
in approximately 5% of UC (Lae et al., 2010). A single arm
phase II study of patients with Her2 positive UC (defined as
2+ or 3+ by immunohistochemistry, positive FISH, or elevated
serum Her2/neu extracelluar domain) showed an encouraging
70% response rate with the addition of trastuzumab to pacli-
taxel, gemcitabine, and carboplatin (Hussain et al., 2007). Results
are awaited from a European randomized phase 2 study compar-
ing standard chemotherapy with or without trastuzumab in Her2
positive metastatic UC (Beuzeboc et al., 2007). In addition, the
ongoing phase II/III LaMB UK study is randomizing patients with
HER1 and/or HER2 overexpressing locally advanced or metasta-
tic bladder UC to maintenance lapatinib vs. placebo in patients
with stable or responding disease after first-line chemotherapy
(NCT00949455).
The fibroblast growth factor receptor 3 (FGFR3) is another
transmembrane receptor tyrosine kinase which harbors activat-
ing mutations in UC (Iyer and Milowsky, 2012). It has activating
point mutations or amplifications in 50–60% of muscle invasive
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bladder UC (Figure 1). Activating point mutations are more
commonly found in superficial bladder UC than the muscle inva-
sive phenotype (van Rhijn et al., 2010). Cell line and xenograft
studies have shown the anti-cancer effects of inhibiting mutant
FGFR3 (Tomlinson et al., 2007b). Multiple agents which block
this pathway are under active development and the most clini-
cally advanced of these is the Novartis agent TKI12458. Results
are awaited from a phase II trial (NCT00790426) of this agent
as second and third-line therapy for patients with advanced UC.
Patients were stratified by the presence or absence of FGFR3
activating point mutations to determine whether there is pre-
dictive and therapeutic utility in targeting this pathway. In addi-
tion to activating point mutations and amplifications, a recent
report describes oncogenic FGFR3 genetic translocations and
re-arrangements as an alternative mechanism of pathway acti-
vation (Williams et al., 2013). Another study observed FGFR3
overexpression by immunohistochemistry in 42% of FGFR3 wild-
type tumors (Tomlinson et al., 2007a). Whether some or all UC
tumors with FGFR3 activating point mutations, gene amplifi-
cations, gene re-arrangements, or immunohistochemical over-
expression will respond to pathway inhibition remains to be
determined but investigation of such an approach is certainly
warranted.
Activating mutations of theBRAF gene are known to be present
in 7–8% of all cancers and are present across a wide range of
tumor types (Flaherty et al., 2010). Vemurafenib, an orally admin-
istered agent which specifically blocks V600E mutated BRAF, is
highly active in patients with V600E BRAF mutant metastatic
melanoma (Chapman et al., 2011). It has also shown activity
in reported cases of lung cancer and leukemia with this muta-
tion (Dietrich et al., 2012; Gautschi et al., 2012). Data on the
frequency of BRAF mutations in UC are sparse but one small
study detected mutations in 2 of 30 patients studied, of which one
was a V600E mutation (Boulalas et al., 2009). Vemurafenib may
prove to be an active agent in selected UC cases bearing BRAF
mutations.
ANTI-ANGIOGENIC THERAPY
As one of the seven hallmarks of cancer, angiogenesis is known
to play a critical role in the development and proliferation of all
malignancies (Hanahan and Weinberg, 2011). UC tumors with
increased angiogenesis as measured by higher microvessel den-
sity or higher serum levels of vascular endothelial growth factor
(VEGF) have been shown to have worse prognosis (Bochner et al.,
1995; Bernardini et al., 2001).
Bevacizumab is a monoclonal antibody directed against cir-
culating VEGF. It has shown clinical benefit in colorectal, lung,
and other cancers. A phase II trial of cisplatin/gemcitabine and
bevacizumab as first-line therapy for metastatic UC revealed
an encouraging overall response rate of 72% and an overall
survival of 20.4 months (Hahn et al., 2011). To further inves-
tigate this promising finding, a phase III study is currently
accruing which randomizes patients to standard therapy with
cisplatin/gemcitabine± bevacizumab (NCT00942331).
Sunitinib is a multi-targeted TKI with activity against ?VEGFR,
PDGFR, Kit, FLT3, and RET. It was studied in the first-line setting
combined with gemcitabine/cisplatin but the combination was
found to be associated with severe hematologic toxicity (Galsky
et al., 2010). Two phase II trials have evaluated its use as single agent
therapy (one as first-line treatment in cisplatin ineligible patients
and the other as second-line treatment) with response rates of
5–8% reported (Bellmunt et al., 2011; Gallagher et al., 2011b).
Pazopanib is a TKI against ?VEGFR, PDGFR, and Kit. It was stud-
ied as a single agent in a phase II trial in chemo-refractory advanced
UC and demonstrated a 17% response rate, although the results
of this study are difficult to interpret due to the non-standard
evaluation schedule used (Necchi et al., 2012).
IMMUNOTHERAPY
Adjuvant intravesical immunotherapy with Bacillus Calmette–
Guerin (BCG) for non-muscle invasive bladder cancer is a stan-
dard therapy, and demonstrates the importance of immune stim-
ulation in the treatment of UC (Hussain et al., 2009). Based on,
investigation of immune checkpoint inhibitors in UC is warranted.
For example, CTLA-4 blockade with ipilimumab has shown effi-
cacy in metastatic melanoma (Hodi et al., 2010). An exploratory
study of its use in the neoadjuvant setting for 12 patients with
bladder UC showed it to be well tolerated. There was increased fre-
quency of CD4+ ICOS high T cells in tumor tissues and in the sys-
temic circulation after ipilimumab suggesting that an anti-tumor
immune response was induced, although the clinical relevance of
this finding is as yet unknown (Carthon et al., 2010). Sipuleucel-T
is an autologous active cellular immunotherapy which improves
survival in metastatic castrate refractory prostate cancer (Kantoff
et al., 2010). Using the same platform to activate peripheral-blood
mononuclear cells against Her2 expressing UC cells, an ongoing
randomized phase II study is investigating the efficacy of DN24-02
in Her2 positive UC in the adjuvant setting (NCT01353222). There
are also a number of anti-tumor vaccines under investigation in
UC targeting antigens such as human chorionic gonadotropin-
beta (β-hCG) and NY-ESO-1 (NCT00948961; Sharma et al., 2008;
Morse et al., 2011).
CONCLUSION
The development of precise anti-cancer agents which target known
molecular aberrations presents a considerable challenge for clinical
trial design. The accepted standard for demonstration of efficacy
of new cancer therapies has been the phase III randomized con-
trolled trial design. However enrolling patients to such trials in
the new era of precision medicine will pose logistic and ethical
challenges. The subdivision of patients into smaller and smaller
groups based on detailed molecular analysis is re-defining cancer
as “a thousand rare diseases” (Kerr, 2012). Accruing large num-
bers of patients to trials evaluating medicines that are targeted
at small subsets will become increasingly difficult. In addition,
a randomized trial design may deny or delay patients’ access to
highly active medicines, which could be ethically questionable.
One way to meet the challenge of accruing sufficient number of
patients to trials of these new agents would be to allow enrollment
of all patients who have the molecular profile expected to benefit
from treatment regardless of cancer site of origin. Agents in these
single arm trials of enriched patient populations which demon-
strate high-levels of therapeutic activity should be considered for
regulatory approval, with the proviso that careful post-marketing
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safety follow-up and ongoing trials are undertaken in large cohorts
to validate the results.
To maximize the efficacy of new treatments, a combinator-
ial rather than single agent approach may be required, similar
to combination cytotoxic chemotherapy for UC. Dual therapy
with TKIs blocking different points in the same signaling path-
way has improved efficacy over single agent therapy in metastatic
melanoma (Flaherty et al., 2012). Similarly, synchronous block-
ade of parallel growth signaling pathways has improved efficacy
in breast cancer (Baselga et al., 2012). Combinations of different
therapeutic modalities such as chemotherapy with anti-angiogenic
agents is also under investigation as discussed above.
Despite major strides in other malignancies, the treatment of
advanced UC has made no major progress over the past 10 years.
The ultimate goal of treatment for patients with metastatic can-
cer is to induce long term disease remission or stability. UC may
be driven by alterations of different signaling molecules including
HER2, FGFR3, and members of the PI3K pathway. Indeed, it may
itself prove to be “a thousand rare diseases” with individual treat-
ments dictated by the molecular profile of a given patients tumor. It
is unclear which of the treatment strategies currently under inves-
tigation will be most beneficial for UC patients but the ongoing
phase III study of bevacizumab added to conventional chemother-
apy places this compound closest to the regulatory finishing line
should the trial prove positive. Targeting specific signaling path-
ways along with pursuing the other avenues of research discussed
above will hopefully lead us to new effective therapies for this lethal
disease.
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